Spondylodiscitis, though rare, poses considerable diagnostic and therapeutic challenges, often requiring prolonged hospitalization, extensive imaging, long-term antibiotic therapy, and sometimes surgical intervention. In resource-limited healthcare systems, its economic burden remains poorly characterized. This study aimed to provide a cost-based evaluation of spondylodiscitis management in Türkiye, assessing clinical, radiological, and laboratory parameters from diagnosis to treatment completion. A retrospective single-center analysis was conducted on patients diagnosed and treated for spondylodiscitis between January 2012 and December 2023. After applying strict inclusion and exclusion criteria to avoid confounding, 32 patients were analyzed. Costs were calculated using reimbursement rates from the Social Security Institution of Türkiye and converted to Euros. Subgroup comparisons were made between primary versus secondary cases, culture-positive versus culture-negative cases, and patients with versus without comorbidities. Nonparametric analyses were performed due to non-normal cost distributions. The cohort included 18 females and 14 males with a mean age of 57.5 years. Pathogens were identified in 60.6% of cases, with Staphylococcus aureus being most common. Nineteen patients (54.3%) required surgical intervention. The mean antibiotic duration was 10.8 weeks. The total treatment cost was €50,128.77, averaging €1,566.52 per patient. Secondary spondylodiscitis, absence of pathogen identification, and lack of comorbidities tended to increase costs, though no subgroup difference reached statistical significance. Surgical interventions represented the largest cost component. The mean per-patient cost of spondylodiscitis management in Türkiye was markedly lower than figures reported in high-income countries. Early diagnosis, pathogen identification, and standardized surgical decision-making may reduce unnecessary expenditures while ensuring effective clinical outcomes.
Background: Meningiomas exhibit considerable biological heterogeneity that is not fully captured by histopathological grading. Tissue-based molecular markers may provide complementary insight into tumor biology within routine diagnostic settings. Methods: Formalin-fixed paraffin-embedded tissue samples from 65 intracranial meningiomas and 13 non-neoplastic controls were analyzed. Aquaporin-4 (AQP4) expression was assessed using immunohistochemistry, while miR-216a, miR-320a, and LINC00461 levels were quantified by means of RT-qPCR. Expression patterns were compared across groups and evaluated in relation to histological grade. Results: AQP4 expression was significantly reduced in meningiomas compared with controls and showed a further decrease in higher-grade tumors. Although expression of miR-216a and miR-320a was also lower in tumor samples, these differences did not reach statistical significance. Correlation analysis revealed modest but significant associations between AQP4 and miR-216a, as well as between miR-216a and miR-320a. Individual markers demonstrated limited discriminatory performance; however, combined expression patterns suggested underlying molecular variability across tumor grades. Conclusions: Our findings indicate that AQP4 downregulation represents a consistent feature in meningiomas, while associated microRNA alterations may reflect coordinated but context-dependent expression patterns. Although these markers are not sufficient as standalone diagnostic tools, their combined tissue-level assessment may provide complementary information on tumor heterogeneity. These findings should be interpreted as exploratory and highlight the need for further validation in larger and mechanistic studies.